7414-83-7 Usage
Description
Agents in the first generation (e.g., etidronate disodium and tiludronate) that were dosed continuously
produced poorly mineralized bone, because there was no interval for appropriate bone mineralization to
occur. Subsequent studies that used a cyclic dosing schedule (400 mg/day for 2 weeks, followed by 2.5 months
of calcium supplementation only) showed improvement in bone mineralization. Etidronate has been
approved for treatment of Paget's disease of the bone but not for treatment of osteoporosis. Tiludronate
is approximately 10-fold more potent than etidronate and, when given orally for 6 months (200, 400, or 800
mg/day), increases BMD by 2%. No further bone loss was detected in patients 6 months after cessation of
therapy.
Chemical Properties
White Crystalline Solid
Uses
Different sources of media describe the Uses of 7414-83-7 differently. You can refer to the following data:
1. Used as a calcium regulator. A bisphosphonate bone resorptive inhibitor
2. Etidronate disodium is a bisphosphonate antiresorptive agent,it is used as a calcium regulator.
3. Sequestering and chelating agent; scale and corrosion inhibitor.
Definition
ChEBI: An organic sodium salt resulting from the replacement of two protons from etidronic acid (one from from each of the phosphonic acid groups) by sodium ions.
Biochem/physiol Actions
Etidronate helps to guard chronic ocular hypertension prompted retinal oxidative stress. It stimulates the development of retinal ganglion cells through insulin-like growth factor 1 (IGF-1) signaling pathway. It may possess neuroprotective effects in in vivo and in vitro rat model of glaucoma. Etidronate belongs to bisphosphonates.
Safety Profile
Poison by intravenous
and subcutaneous routes. Moderately toxic
by ingestion. An experimental teratogen.
Other experimental reproductive effects.
When heated to decomposition it emits
toxic fumes of POx, and Na2O.
Veterinary Drugs and Treatments
Etidronate is a first generation bisphosphonate that may be useful
for the treatment of severe hypercalcemia associated with neoplastic
disease. Its use in human medicine has been largely replaced
with newer, more potent bisphosphonates that can be dosed less
often or have fewer adverse effects. Etidronate is also indicated in
humans for the treatment of Paget’s disease and heterotopic ossification
(e.g., after total hip replacement).
Check Digit Verification of cas no
The CAS Registry Mumber 7414-83-7 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 7,4,1 and 4 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 7414-83:
(6*7)+(5*4)+(4*1)+(3*4)+(2*8)+(1*3)=97
97 % 10 = 7
So 7414-83-7 is a valid CAS Registry Number.
InChI:InChI=1/C2H8O7P2.2Na/c1-2(3,10(4,5)6)11(7,8)9;;/h3H,1H3,(H2,4,5,6)(H2,7,8,9);;/q;2*+1/p-4
7414-83-7Relevant articles and documents
One-pot synthesis of phosphinylphosphonate derivatives and their anti-tumor evaluations
Deschamp, Julia,Dussart-Gautheret, Jade,Lecouvey, Marc,Legigan, Thibaut,Migianu-Griffoni, Evelyne,Monteil, Maelle
, (2021/12/24)
This paper reports on the synthesis of new hydroxymethylene-(phosphinyl)phosphonates (HMPPs). A methodology has been developed to propose an optimized one-pot procedure without any intermediate purifications. Various aliphatic and (hetero)aromatic HMPPs were synthesized in good to excellent yields (53–98%) and the influence of electron withdrawing/donating group substitution on aromatic substrates was studied. In addition, the one-pot synthesis of HMPP was monitored by31P NMR spectroscopy, allowing effective control of the end of the reaction and identification of all phosphorylated intermediate species, which enabled us to propose a reaction mechanism. Optimized experimental conditions were applied to the preparation of biological relevant aminoalkyl-HMPPs. A preliminary study of the complexation to hydroxyapatite (bone matrix) was carried out in order to verify its lower affinity towards bone compared to bisphosphonate molecules. Moreover, in vitro anti-tumor activity study revealed encouraging antiproliferative activities on three human cancer cell lines (breast, pancreas and lung).
Optimized synthesis of etidronate
Kovacs, Rita,Nagy, David Illes,Gruen, Alajos,Balogh, Gyoergy Tibor,Garadnay, Sandor,Greiner, Istvan,Keglevich, Gyoergy
, p. 733 - 737 (2013/12/04)
The synthesis of Etidronate (as the disodium salt) by the reaction of acetic acid with phosphorus trichloride/phosphorus acid in methanesulfonic acid was studied and optimized. We showed that it is enough to use 3.2 equivalents of the phosphorus trichlori
Aminohydroxypropane esters of hydroxyethylidenebisphosphoric acid.
Chuiko, Alexey,Philonenko, Ludmila,Borisevich, Anatoly,Lozinsky, Miron
, p. 66 (2007/10/03)
-
